# MSAC (Australia) - Tisagenlecleucel (Kymriah) HTA Report

## Report Overview
**Agency:** Medical Services Advisory Committee (MSAC), Australia
**Note:** NOT PBAC - CAR-T therapy reviewed as a 'technology' rather than a 'medicine'
**Product:** Tisagenlecleucel (Kymriah)
**Sponsor:** Novartis Australia
**Funding Pathway:** National Health Reform Agreement (NHRA) - Highly Specialised Therapy

## Important Clarification: MSAC vs. PBAC

### Why MSAC, Not PBAC?

**Key Distinction:**
CAR-T cell therapy is being managed as a **technology** rather than a traditional pharmaceutical 'medicine', therefore funding must be sought through the **Medical Services Advisory Committee (MSAC)** rather than the **Pharmaceutical Benefits Advisory Committee (PBAC)**.

**Rationale:**
- CAR-T involves complex medical procedures (leukapheresis, cell processing, specialized administration)
- Not a conventional pharmaceutical product
- Requires specialized infrastructure and expertise
- Procedure-based reimbursement model more appropriate

**Funding Mechanism:**
Tisagenlecleucel funded through the **National Health Reform Agreement (NHRA)** as a **highly specialised therapy**, with costs shared between Commonwealth and States/Territories.

---

## MSAC Applications

### 1. Acute Lymphoblastic Leukaemia (pALL) - Application 1519

**Official URL:** http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1748-public
**Alternative URL:** https://www.msac.gov.au/applications/1519-1

**Application Title:** Tisagenlecleucel (CTL019) for treatment of confirmed relapsed/refractory CD19-positive acute lymphoblastic leukaemia in children and young adults up to 25 years old

**Review Status:** Application 1748 represents a review/update of the original assessment

**MSAC Meetings:**
- November 2018 meeting
- March 2019 meeting
- Out-of-session meeting in April 2019

**MSAC Decision:**
Following consideration at multiple meetings, the committee **supported funding** of tisagenlecleucel (Kymriah) for treatment of acute lymphoblastic leukaemia in paediatric and young adult patients (pALL) as a **highly specialised therapy** through the National Health Reform Agreement (NHRA).

---

### 2. Diffuse Large B-cell Lymphoma (DLBCL) - Application 1519.1

**Official URL:** http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1519.1-public
**Alternative URL:** https://www.msac.gov.au/applications/1519-1

**Application Title:** Tisagenlecleucel (CTL019) for treatment of relapsed or refractory diffuse large B-cell lymphoma

**Purpose of Meeting:**
The purpose of the MSAC meeting was to allow the committee to **seek advice on patient eligibility** for treatment and other aspects of patient management, in light of recent MSAC consideration of Kymriah (tisagenlecleucel, sponsored by Novartis Australia).

**Key Focus Areas:**
1. Patient eligibility criteria refinement
2. Patient selection and assessment processes
3. Treatment pathways and management protocols
4. Infrastructure and center qualification requirements

---

## Executive Summary

### MSAC Assessment Process

**Comprehensive Evaluation:**
MSAC conducts thorough assessments including:
1. **Clinical evidence review:**
   - Safety and effectiveness from clinical trials
   - Comparative evidence vs. standard of care
   - Long-term outcomes and durability of response

2. **Economic evaluation:**
   - Cost-effectiveness analysis
   - Budget impact assessment
   - Healthcare resource utilization

3. **Implementation considerations:**
   - Healthcare system capacity
   - Qualified treatment centers
   - Training and education requirements
   - Patient access pathways

**Multi-Stakeholder Input:**
- Clinical experts and specialist colleges
- Patient advocacy groups
- Health economists
- State and territory health departments
- TGA (Therapeutic Goods Administration) regulatory status

---

## Clinical Evidence Review

### Pediatric/Young Adult Acute Lymphoblastic Leukaemia

**Pivotal Trial: ELIANA Study**
- Phase 2, single-arm, multicenter trial
- Pediatric and young adult patients (â‰¤25 years)
- Relapsed or refractory B-cell ALL
- At least 2 prior therapies or post-transplant relapse

**Key Efficacy Outcomes:**
- Overall remission rate (ORR)
- Complete remission (CR) and CR with incomplete blood count recovery (CRi)
- Minimal residual disease (MRD) negativity
- Duration of remission
- Overall survival

**Safety Outcomes:**
- Cytokine release syndrome (CRS) incidence and severity
- Neurological toxicities
- Infections and B-cell aplasia
- Long-term adverse events

**MSAC Assessment:**
Committee evaluated the evidence base and judged it sufficient to support funding for this indication with high unmet medical need.

---

### Diffuse Large B-cell Lymphoma

**Pivotal Trial: JULIET Study**
- Phase 2, single-arm, multicenter trial
- Adult patients with relapsed or refractory DLBCL
- After 2 or more lines of systemic therapy
- Ineligible for or relapsed post autologous stem cell transplant

**Key Efficacy Outcomes:**
- Overall response rate (ORR)
- Complete response (CR) rate
- Duration of response
- Progression-free survival (PFS)
- Overall survival (OS)

**Comparator Consideration:**
- Historical data from salvage chemotherapy trials
- Real-world evidence from Australian registries
- Outcomes in similar patient populations

**MSAC Deliberations:**
Committee sought additional advice on:
- Patient eligibility refinement
- Optimal timing of CAR-T in treatment pathway
- Patient selection factors influencing outcomes
- Management protocols during and after treatment

---

## Economic Evaluation

### Cost-Effectiveness Analysis

**Economic Model Structure:**
- Partitioned survival model or decision tree
- Time horizon: Lifetime (given potential for cure)
- Perspective: Australian healthcare system
- Discount rate: 5% per annum (Australian standard)

**Key Inputs:**

1. **Costs:**
   - Acquisition cost of tisagenlecleucel
   - Leukapheresis and cell processing
   - Lymphodepleting chemotherapy
   - Administration and hospitalization
   - Toxicity management (CRS, neurotoxicity)
   - Long-term follow-up and monitoring
   - Comparator treatment costs

2. **Outcomes:**
   - Quality-adjusted life years (QALYs)
   - Life years gained
   - Response rates and durability
   - Survival projections

3. **Utilities:**
   - Health state utilities (remission, relapse, palliative care)
   - Quality of life assessments
   - Adverse event disutilities

**Incremental Cost-Effectiveness Ratio (ICER):**
MSAC evaluates ICER against Australian willingness-to-pay thresholds, typically $50,000-$75,000 AUD per QALY, with flexibility for life-saving therapies and high unmet need.

**Sensitivity Analyses:**
- Uncertainty in long-term survival extrapolation
- Treatment effect duration
- Cost variations
- Utility value assumptions
- Discount rate impact

---

## Budget Impact Analysis

### Financial Implications for Australian Healthcare System

**Patient Population Estimation:**
1. **Incidence/Prevalence:**
   - ALL: Annual new cases of relapsed/refractory disease in eligible age group
   - DLBCL: Annual cases of relapsed/refractory disease after 2+ lines

2. **Eligibility Criteria:**
   - CD19-positive disease
   - Adequate organ function and performance status
   - Access to qualified CAR-T center
   - Medically appropriate for intensive therapy

3. **Market Uptake:**
   - Year-by-year projections
   - Consideration of alternative CAR-T products
   - Capacity constraints at treatment centers

**Budget Impact Components:**
- **Direct costs:** Tisagenlecleucel acquisition and administration
- **Infrastructure costs:** CAR-T center setup and maintenance
- **Training costs:** Healthcare professional education
- **Offset savings:** Reduced use of conventional salvage therapies
- **Long-term costs/savings:** Durable remissions vs. ongoing treatment

**NHRA Funding Arrangements:**
- Cost-sharing between Commonwealth and States/Territories
- Negotiated pricing arrangements (confidential)
- Activity-based funding for procedures
- Specialized services funding streams

---

## Implementation and Healthcare System Requirements

### CAR-T Treatment Centers in Australia

**Qualification Requirements:**

1. **Clinical Expertise:**
   - Hematology-oncology specialists with CAR-T training
   - ICU physicians experienced in CAR-T toxicity management
   - Apheresis team and facilities
   - Pharmacy expertise in CAR-T handling
   - Nursing staff trained in CAR-T care

2. **Infrastructure:**
   - Apheresis center (accredited)
   - Cryopreservation and cell processing arrangements
   - Inpatient beds with appropriate monitoring
   - ICU beds with immediate access
   - Laboratory capabilities for monitoring

3. **Support Services:**
   - Neurology consultation for ICANS management
   - Infectious disease support
   - Transfusion medicine services
   - Social work and psychosocial support

4. **Accreditation:**
   - JACIE (Joint Accreditation Committee ISCT-Europe & EBMT) or equivalent
   - State/territory health department approval
   - Manufacturer certification and training completion

**Geographic Distribution:**
- Major metropolitan centers (Sydney, Melbourne, Brisbane, Perth, Adelaide)
- Potential for regional referral arrangements
- Telemedicine for follow-up where appropriate

---

### Patient Pathway in Australia

**Pre-Treatment Phase:**
1. Identification of relapsed/refractory disease at local center
2. Referral to qualified CAR-T center for assessment
3. Multidisciplinary team review of eligibility
4. Patient/family education and informed consent
5. Insurance/funding approval (MBS, NHRA arrangements)

**Leukapheresis and Manufacturing:**
1. Apheresis procedure at qualified center
2. Cryopreservation and shipment to manufacturing facility
3. Manufacturing period (~3-4 weeks)
4. Bridging therapy if needed (disease control during manufacturing)

**CAR-T Administration:**
1. Admission to CAR-T center
2. Lymphodepleting chemotherapy (conditioning)
3. Tisagenlecleucel infusion
4. Inpatient monitoring (typically 7-14 days minimum)
5. CRS and ICANS surveillance and management
6. Discharge planning and outpatient transition

**Post-Treatment Follow-up:**
1. Frequent outpatient visits (weeks 1-3 post-discharge)
2. Response assessments (1, 3, 6, 12 months, then annually)
3. Long-term toxicity monitoring
4. B-cell aplasia management (immunoglobulin replacement)
5. Registry participation for real-world evidence

---

## TGA Regulatory Status

### Therapeutic Goods Administration (TGA) Approval

**Regulatory Pathway:**
Tisagenlecleucel (KYMRIAH) approved by TGA for use in Australia.

**Official TGA Resource:**
https://www.tga.gov.au/resources/prescription-medicines-registrations/kymriah-novartis-pharmaceuticals-australia-pty-ltd

**Approved Indications:**
Aligned with international approvals (EMA, FDA) for:
- Relapsed/refractory B-cell ALL in pediatric and young adult patients
- Relapsed/refractory DLBCL in adult patients after 2+ systemic therapies

**Post-Market Surveillance:**
- Adverse event reporting through TGA
- Participation in international safety registries
- Risk management plan implementation

---

## Patient Access and Equity Considerations

### Geographic Challenges

**Australia-Specific Issues:**
1. **Large geographic distances:**
   - Rural and remote patients require travel to metropolitan centers
   - Financial and logistical burdens on families
   - Time away from home and support networks

2. **State/Territory Variations:**
   - Different healthcare infrastructure across jurisdictions
   - Variation in CAR-T center availability
   - Coordination of care across state borders

**Mitigation Strategies:**
- Patient Assisted Travel Schemes (PATS) in most states/territories
- Accommodation support near treatment centers
- Telemedicine for follow-up consultations
- Regional hematologist collaboration with CAR-T centers

---

### Indigenous Health Equity

**Considerations for Aboriginal and Torres Strait Islander Peoples:**
- Cultural appropriateness of treatment discussions
- Family and community involvement in decision-making
- Interpreter services and culturally appropriate education materials
- Coordination with Aboriginal Medical Services
- Recognition of barriers (historical, social, economic)
- Targeted outreach and engagement strategies

---

## Real-World Evidence Collection

### Australian Registry Participation

**National Data Collection:**
Patients treated with tisagenlecleucel in Australia contribute to:
1. **Manufacturer global registries**
2. **Australian national cancer registries**
3. **CAR-T specific registries** for outcomes tracking

**Data Elements:**
- Patient demographics and disease characteristics
- Treatment details and outcomes
- Adverse events and toxicity management
- Healthcare utilization
- Long-term survival and quality of life

**Purpose:**
- Validate clinical trial findings in Australian population
- Inform future MSAC reassessments
- Quality assurance for CAR-T centers
- International comparative data

---

## MSAC Recommendations and Outcomes

### Funding Decisions Summary

**Acute Lymphoblastic Leukaemia (pALL):**
- **SUPPORTED** for public funding
- Through National Health Reform Agreement (NHRA)
- As a highly specialised therapy
- For pediatric and young adult patients up to 25 years
- Following multiple MSAC meetings and detailed consideration

**Diffuse Large B-cell Lymphoma (DLBCL):**
- Additional advice sought on patient eligibility and management
- Reflects complexity of patient selection in this indication
- Focus on optimizing patient outcomes through appropriate selection

**Conditions:**
- Treatment in qualified, accredited CAR-T centers only
- Appropriate patient selection following eligibility criteria
- Registry participation for real-world evidence
- Compliance with manufacturer risk management plans

---

## Comparison with PBAC Process

### MSAC vs. PBAC Pathways

**PBAC (Pharmaceutical Benefits Advisory Committee):**
- Reviews conventional medicines for PBS (Pharmaceutical Benefits Scheme) listing
- Focus on pharmaceutical products
- Reimbursement through community or hospital pharmacy

**MSAC (Medical Services Advisory Committee):**
- Reviews medical services and technologies
- Focus on procedures and complex interventions
- Reimbursement through MBS (Medicare Benefits Schedule) or specialized funding

**Why Tisagenlecleucel Goes to MSAC:**
1. Complex procedure requiring specialized medical services
2. Not dispensed like traditional pharmaceuticals
3. Requires infrastructure and expertise beyond pharmacy
4. Procedure-based reimbursement more appropriate
5. Fits NHRA highly specialized therapy framework

---

## Future Considerations

### Evolution of CAR-T Assessment in Australia

**Emerging Issues:**
1. **Multiple CAR-T products:**
   - Comparison between tisagenlecleucel and axicabtagene ciloleucel
   - Evidence for product selection
   - Market dynamics and pricing

2. **Expanded Indications:**
   - Follicular lymphoma and other B-cell malignancies
   - Earlier lines of therapy
   - Combination strategies

3. **Long-term Outcomes:**
   - 5-year and 10-year survival data
   - Late adverse effects
   - Second malignancies
   - Quality of life in long-term survivors

4. **Healthcare System Capacity:**
   - Expansion of CAR-T center network
   - Training of additional specialists
   - Demand management
   - Equitable access across regions

---

## Key Publications and Resources

### Official MSAC Documents

**Application Summaries:**
- Application 1519/1748 (pALL): http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1748-public
- Application 1519.1 (DLBCL): http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1519.1-public
- MSAC Applications Portal: https://www.msac.gov.au/applications/1519-1

### Australian Clinical Resources

**Australian Prescriber Article:**
"Tisagenlecleucel for B-cell cancers"
**URL:** https://australianprescriber.tg.org.au/articles/tisagenlecleucel-for-b-cell-cancers.html

**The Blood Unit - Patient FAQ:**
"FAQ about CAR-T cell therapies for Blood and Marrow cancers"
**URL:** https://thebloodunit.com.au/news/faq-about-cart-cell-therapies-for-blood-and-marrow-cancers/

### Regulatory Resources

**TGA Product Information:**
https://www.tga.gov.au/resources/prescription-medicines-registrations/kymriah-novartis-pharmaceuticals-australia-pty-ltd

**Parliamentary Research:**
"Approval processes for new drugs and novel medical technologies"
**URL:** https://www.aph.gov.au/DocumentStore.ashx?id=31af4ba8-5add-4891-8b85-085adc90ba33&subId=693488

---

## Conclusions

### MSAC's Approach to Tisagenlecleucel

**Key Features:**
1. **Technology-Based Assessment:**
   - Recognition that CAR-T is more than a medicine
   - Appropriate use of MSAC rather than PBAC pathway
   - Funding through NHRA highly specialized therapy mechanism

2. **Rigorous Evidence Evaluation:**
   - Comprehensive clinical and economic assessment
   - Multiple committee meetings for complex decisions
   - Ongoing deliberation on patient eligibility and management

3. **Implementation Focus:**
   - Emphasis on qualified center requirements
   - Patient pathway development
   - Real-world evidence collection

4. **Equity Considerations:**
   - Geographic access challenges acknowledged
   - Indigenous health considerations
   - Patient support mechanisms

**Overall Outcome:**
MSAC supported public funding for tisagenlecleucel in **pediatric/young adult ALL**, demonstrating confidence in the evidence base and recognition of high unmet need. For **DLBCL**, additional deliberations on patient eligibility reflect the complexity of this indication and commitment to optimizing patient selection for best outcomes.

**Australian Healthcare System Integration:**
The MSAC process exemplifies Australia's approach to evaluating and funding complex medical technologies, balancing:
- Innovation and patient access
- Evidence requirements and uncertainty
- Healthcare system capacity and sustainability
- Equity across diverse geography and populations

---

*Report compiled from MSAC official documents and publicly available Australian sources*
*Last updated: November 2025*
